贝塔阻断剂在高血压治疗中的使用率
Brandon J Skory1, John Arko1, Laila Terkawi1
1College of Pharmacy, Northeast Ohio Medical University, Rootstown, OH, USA.
概括
在美国,β阻塞剂经常被不适当地用于高血压. 这项研究发现,超过93%的β阻断剂处方缺乏令人信服的指示,特别是在老年人中.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 不建议使用β抑制剂作为高血压 (HTN) 的一线治疗方法,除非存在特定的强迫性指示.
- 尽管有指导方针,但有证据表明,β抑制剂往往不适当地被处方给美国成年人HTN.
研究的目的:
- 为了确定beta阻断剂在不同时使用其他一线抗高血压药物的情况下对高血压的处方率.
- 在高血压管理中识别与不适当的β阻断剂处方相关的因素.
主要方法:
- 分析国家门诊医疗调查数据从2013-2018年 (不包括2017年).
- 包括接受高血压治疗的成年患者的办公室访问.
- 该研究涵盖了5191次未加权访问,占全国2.47亿次.
主要成果:
- 在21.8%的分析访问中,规定了β-阻断剂.
- 93.6%的β阻塞剂处方根据指南建议被认为是不合适的.
- 年龄较大 (≥65岁) 和血压升高增加了对β阻断剂处方的可能性.
结论:
- 在美国门诊机构中,不适当的β阻塞剂在没有令人信服的指示的情况下处方高血压是非常普遍的.
- 老年人和血压升高的患者有更高的风险不适当的处方.
- 需要提供者教育和临床决策支持,以改善高血压管理.
相关概念视频
Prevalence and Incidence
1.9K
In statistical epidemiology and health sciences, two essential metrics—prevalence and incidence—are fundamental for understanding disease dynamics within a population. These measures enable public health officials, epidemiologists, and researchers to assess the burden of diseases, allocate resources effectively, and design impactful public health policies and interventions.
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
1.9K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
561
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
561
Hypertension I: Introduction
965
Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
965
Hypertension II: Pathophysiology
1.0K
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
1.0K
Hypertension V: Nursing Management
495
The nursing management of hypertension involves accurately assessing symptoms, making a comprehensive nursing diagnosis, collaborating with patients to set goals, and implementing targeted interventions to mitigate the condition's impact and improve patient well-being.Comprehensive AssessmentThe initial step in nursing care for hypertension involves a thorough patient assessment. It includes evaluating symptoms such as headaches, dizziness, blurred vision, and previous hypertension episodes.
495
Depolarizing Blockers: Pharmocokinetics
612
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
612


